Evidence map›Paper›PMID 33287410›Full record

ArticleInternational journal of molecular sciences2020

Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput

Sarah Gilgunn, Keefe Murphy, Henning Stöckmann, Paul J Conroy, T Brendan Murphy, R William Watson, Richard J O'Kennedy, Pauline M Rudd, Radka Saldova

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Sarah GilgunnSchool of Biotechnology, Dublin City University, D09 V209 Dublin 9, Ireland.ORCID 0000-0003-3547-5228
Keefe MurphyDepartment of Mathematics and Statistics, Maynooth University, Maynooth, W23 F2K8 Co. Kildare, Ireland.ORCID 0000-0002-7709-3159
Henning StöckmannNIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099 Co. Dublin, Ireland.ORCID 0000-0002-2409-5476
Paul J ConroyDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Nursing and Health Science, Monash University, Melbourne, VIC 3800, Australia.ORCID 0000-0002-9748-4704
T Brendan MurphyUCD School of Mathematics and Statistics, University College Dublin, D04 V1W8 Dublin 4, Ireland.ORCID 0000-0002-5668-7046
R William WatsonConway Institute of Biomolecular and Biomedical Research, University College Dublin, D04 V1W8 Dublin 4, Ireland.
Richard J O'KennedySchool of Biotechnology, Dublin City University, D09 V209 Dublin 9, Ireland.
Pauline M RuddNIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099 Co. Dublin, Ireland.
Radka SaldovaNIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, A94 X099 Co. Dublin, Ireland.ORCID 0000-0001-5085-5080
University College Dublin · IEDublin City University · IEBioprocessing Technology Institute · SGMonash University · AUNational Institute for Bioprocessing Research and Training · IENational University of Ireland, Maynooth · IE

Funding

EUFP7 program HighGlycan (278535)European Union Seventh Framework Programme 260600-GlycoHITIrish cancer society PCI11WATScience Foundation Ireland 13/SIRG/2164Science Foundation Ireland 15/IA/3104
6 · The paper itself

Abstract

The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide. This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa to the more invasive aggressive form remains poorly understood. It is now universally accepted that glycan expression patterns change with the cellular modifications that accompany the onset of tumorigenesis. The aim of this study was to investigate if differential glycosylation patterns could distinguish between indolent, significant, and aggressive PCa. Whole serum

Indexed as

BiomarkersMetabolomeMetabolomicsAgedChromatography, High Pressure LiquidGlycoproteinsHigh-Throughput Screening AssaysHumansMaleMiddle AgedNeoplasm StagingPolysaccharidesProstatic NeoplasmsBiomarkersGlycoproteinsPolysaccharidesaggressivebiomarkersglycosylationindolentprostate cancersignificant

Identifiers

PMID33287410
PMCPMC7730228
OpenAlexW3108436536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.